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Abstract  
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause 
of liver disease, nonalcoholic steatohepatitis (NASH) and fibrosis in obese patients identifies the 
risk group with increased incidence of liver-related deaths.  
AIM: To clarify the role of serum adiponectin and its receptor liver gene expression in the 
progression of liver damage in NAFLD.  
METHODS: Fifty four (54) obese patients with NAFLD preliminary diagnosed by liver ultra-sound 
were recruited. Full medical history, anthropometric measurement, biochemical studies, serum 
adiponectin level, liver biopsy for histological examination and NAS score to identify NASH patients, 
and assessment of adiponectin receptor gene expression by RT-PCR, were conducted for each 
patients. Fifteen ages matched average weight healthy adult had been chosen as a control for 
serum adiponectin level.  
RESULTS: According to NAS score, patients were divided into non- NASH (8 patients), and NASH 
(46 patients). Serum adiponectin level was significantly lower in NAFLD patients compared to 
normal participants (p < 0.004). Serum adiponectin level was lower in NASH patients (4.437 ± 
2.569 ng/dl in NASH vs. 5.138 ± 2.841 ng/dl in non-NASH). Adiponectin receptor liver gene 
expression was lower in NASH patients (0.8459 ± 0.4671 vs. 1.0688 ± 0.3965 in non-NASH).  
CONCLUSION: Both adiponectin deficiency and resistance had a role in progression of simple liver 
steatosis to severe injury in obese patients. 
 
 
 
 
 
 
Introduction 
 
Nonalcoholic fatty liver disease (NAFLD) is 
closely associated with obesity and insulin resistance, 
and is now recognized to represent the hepatic 
manifestation of the metabolic syndrome. Since the 
term nonalcoholic steatohepatitis (NASH) was first 
coined by Ludwig et al. in 1980, [1] the prevalence of 
NAFLD has risen rapidly in parallel with the dramatic 
rise in population levels of obesity and diabetes, [2] 
resulting in NAFLD, now representing the most 
common cause of liver disease in the western world 
[3]. 
Among morbidly obese patients undergoing 
bariatric surgery, the prevalence of simple fatty liver is 
47%, the prevalence of NASH is 27-42%, and 
cirrhosis occurs in 2.9-3.9% [4]. Whilst simple 
steatosis is thought to be a relatively benign entity, 
NASH has the potential to lead to morbidity and 
mortality. 
Adipotectin is a protein which encoded by the 
ADIPO Q gene [5], this gene localized to chromosome 
3q27, a region highlighted as affecting genetic 
susceptibility to type 2 diabetes and obesity [6]. Acute 
injection of recombinant  adiponectin enriched with the 
high molecular weight (HMW) oligomers results in a 
marked activation of AMP activated kinase (AMPK) in 
the liver, while chronic infusion with this protein leads 
to prolonged alleviation of hyperglycemia and insulin 
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resistance [7]. 
Tow adiponectin receptors (Adipo R), have 
been identified, Adipo R1 is abundantly expressed in 
skeletal muscles, whereas adipo R2 is present 
predominantly in the liver [8]. 
Adenovirus-mediated expression of Adipo R1 
or Adipo R2 in the liver of mice significantly increased 
fatty acid oxidation, and tend to decrease hepatic 
triglycerides content [9]. Obesity decrease plasma 
adiponectin level and Adipo R1/R2 expression, 
causing adiponectin resistance [10].  
Mice without adiponectin show an increased 
lipid accumulation under normal feeding; this pre-
existing hepatic steatotic condition might be the direct 
consequence of dysregulated mitochondrial 
respiratory chain [11]. Adiponectin treatment restores 
the mitochondrial respiratory chain (MRC) activities, 
decrease the level of mitochondrial lipid peroxidation 
products through regulating hepatic mitochondrial 
functions [9]. 
 
 
Patients and Methods 
 
Patients 
The current study is a prospective study, 
performed in Kasr Al-eini hospital, Internal Medicine 
Out-patient Clinic (Liver and Gastroenterology Clinic), 
Faculty of Medicine, Cairo University, over a 6 months 
period (June-November 2011).  
NAFLD patients' preliminary diagnosed by 
liver ultrasound scan showing a picture of fatty liver ± 
elevated liver enzymes. 
The selection of participants in this study was 
based on the following inclusion criteria; males and 
females, aged between 18 and 60 years, with Body 
Mass index (BMI) over 30 kg/m
2
, having a bright liver 
on liver ultrasound scan (picture suggestive of hepatic 
steatosis), and no history of alcohol intake. While 
participants with hepatitis C or B infection, patients 
with known causes of liver disease (autoimmune, 
genetic, or drug induced), patients with major 
systemic conditions and pregnant women were 
excluded from the study. 
Fifty four  male and female participants (50 
females and 4 males) had a complete work-up 
including, a detailed medical history, general physical 
examination, anthropometric measurements, serum 
biochemistry profiles; including serum adiponectin, 
hepatitis markers (HCV antibody, and HBVs antigen), 
liver ultrasound scan, and True-cut ultrasound guided 
liver biopsy. 
Fifteen healthy ages matched average weight 
(BMI < 25 Kg/m
2
) participants, with normal 
appearance of the liver during scanning, and normal 
liver enzymes, had been chosen as a control for 
serum adiponectin level. 
The study protocol conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki, and 
was approved by Cairo University Hospital Research 
Ethics Committee (REC) in 28-5-2011 (N-7-2011).  
Written informed consents were obtained from 
all participants in the study. 
 
Methods 
All participants were interviewed for their 
medical history, and information on life style factors. 
The weight and height of each participant were 
measured while the participant was clothed only in a 
light gown, and the body mass index was calculated 
as body weight divided on height squared (Kg/m
2
), 
obesity defined as a BMI ≥ 30 Kg/m
2
. The waist 
circumference was measured midway between the 
lowest rib margin and the iliac crest in a standing 
position, by the same examiner. 
Laboratory investigations, included serum 
alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), γ-glutamyl transpeptidase 
(GGT), alkaline phosphatase (ALP), total and 
conjugated bilirubin, prothrombin concentration, 
fasting blood sugar, and lipid profile ( total cholesterol, 
low density lipoprotein (LDL) cholesterol, high density 
lipoprotein (HDL) cholesterol, and triglycerides). 
Serum Adiponectin level was measured using the 
quantitative Sandwish enzyme immunoassay 
technique. A monoclonal antibody specific for the 
adiponectin or resistin globular domain were used.  
Liver ultrasound scan (US) performed by the 
same operator (MH), using a Toshiba Aplio xv 
scanner equipped with a broad band 2.5-5 MHZ 
curved-array probe to assess the presence of liver 
steatosis ("bright liver"), which was defined and 
graded as: 1- a diffuse hyper echoic echo texture 
(bright liver); 2- increased liver echo texture compared 
with the kidney; 3- vascular blurring; and 4- deep 
attenuation [12].  Steatosis was graded using this 
semi-quantitative scale from 1 to 4.  
All participants were eligible for liver biopsy, 
based on the presence of hepatic steatosis in liver US 
± elevated liver enzymes, and normal prothrombin 
concentration. All the samples were evaluated by the 
same pathologist (AM). They were fixed in ten percent 
neutral buffered formalin, embedded in paraffin 
blocks, then cut into five micrometer thick sections 
and stained with hematoxylin & eosin. They were 
examined under the light microscope for histo-
pathological evaluation. 
In a subsequent analysis of liver biopsies, 
liver damage was assessed by means of the NAFLD 
activity score (NAS), which is the sum of steatosis 
(scale from 0-3), lobular inflammation (scale from 0-3), 
and hepatocellular ballooning (scale from 0-2), 
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according to Kleiner et al, 2005 [13]. This scoring 
system addresses the full spectrum of lesions of 
NAFLD, and allows a diagnostic categorization into 
NASH, border-line NASH, or non- NASH. Fibrosis 
staging (evaluated separately from NAS) from 0-4 
scales (where 0= no fibrosis, and 4= cirrhosis) 
according to the classification set by Brunt, et al in 
1999 [14].  
Our participants were divided into two groups 
according to NAS score; NASH positive patients (46); 
(24 border-line NASH, and 22 NASH "2 of them had 
fibrosis"), and another group had no NASH (8 
patients). 
Quantitative Real time-polymerase chain 
reaction (RT-qPCR) was used for assessment of 
adiponectin receptor gene expressions in liver tissue. 
[15]. Total RNA was extracted from liver tissue using 
SV total RNA isolation system (Promega, Madison, 
WI, USA), RNA purification, Reverse Transcription 
into cDNA using RT-PCR kit (Stratagene, USA), then 
the real-time PCR result was analyzed with the step 
one applied biosystem software.    
 
Statistical Methods 
Data were statistically described in terms of 
mean ± standard deviation (± SD), and frequencies 
(number of cases) and relative frequencies 
(percentages) when appropriate. Comparison of 
numerical variables between the study groups was 
done using Kruskal Wallis test with multiple groups' 
comparisons. For comparing categorical data, Chi 
square (2) test was performed. Exact test was used 
instead when the expected frequency is less than 5. A 
probability value (p value) less than 0.05 was 
considered statistically significant. All statistical 
calculations were done using computer programs 
SPSS (Statistical Package for the Social Science; 
SPSS Inc., Chicago, IL, USA) version 15 for Microsoft 
Windows.  
 
 
Results 
 
The present study included 54 patients (50 
femals 42.6%, and 4 males 7.4%), aged 43.17 ± 7.3 
years, have NAFLD suspected by liver ultrasound 
scan and confirmed by liver biopsy. 15 age-matched 
average weight (BMI < 24.9 kg/m
2
) healthy 
participants were the control group. 
Anthropometric measurements and laboratory 
studies of NAFLD patients are shown in Table 1. 
According to NAS score in liver biopsy of 
NAFLD patients; 46 patients (44 females, and 2 
males) proven to had NASH and border line NASH, 
and only 8 patients (6 females, and 2 males) were 
non-NASH. 
Table 1: Clinical and laboratory data of all NAFLD patients  
Parameter Mean ± SD 
BMI (kg/m²) 34.77 ± 3.761 
Waist (cm) 106.13 ± 14.993 
ALT (IU/L) 33.24 ± 19.061 
AST (IU/L) 33.02 ± 20.141 
GGT (IU/L) 47.56 ± 35.499 
FBS (mg/dl) 92.85 ± 9.472 
Total-C (mg/dl) 206.15 ± 33.093 
LDL-c (mg/dl) 104.19 ± 21.267 
HDL-c (mg/dl) 48.04 ± 14.403 
Triglycerides (mg/dl) 171.56 ± 43.824 
ALT; alanine aminotransferase, AST; aspertate aminotransferase, BMI; body mass index, 
FBS; fasting blood sugar, GGT; gamma glutemyl transpeptidase, HDL-c; high density 
lipoprotein cholesterol, LDL-c; low density lipoprotein cholesterol, Total-C; total cholesterol.  
 
Clinical and laboratory data of NASH and 
non- NASH patients are shown in Table 2. 
Table 2: Clinical and laboratory data of NASH and non-NASH 
patients 
Parameter NASH P value 
Yes 
n.46 
No 
n.8 
Age (years) 42.71 ± 4.52 45.75 ± 6.27 0.29 
BMI (kg/m²) 34.98 ± 3.95 33.59 ± 2.19 0.643 
Waist (cm) 106.65 ± 15.53 103.13 ± 11.78 0.487 
ALT (IU/L) 35.78 ± 19.36 18.63 ± 7.43 0.005* 
AST (IU/L) 34.41 ± 21.41 25.0 ± 6.16 0.223 
GGT (IU/L) 51.63 ± 36.58 24.13 ± 14.62 0.006* 
FBS (mg/dl) 120.72 ± 30.58 121.63 ± 23.97 0.697 
T.cholesterol (mg/dl) 203.0 ± 31.53 224.25 ± 38.22 0.161 
LDL-c (mg/dl) 123.15 ± 18.67 110.13 ± 33.72 0.512 
HDL-c (mg/dl) 47.41 ± 14.95 51.63 ± 10.82 0.176 
Triglycerides (mg/dl) 173.52 ± 43.95 160 ± 44.21 0.465 
N; number of patients in this group, P*; significant less than0.05. 
 
NAFLD patients either NASH or non-NASH 
almost was matched in age (NASH 42.71± 4.52 years, 
non-NASH 45.75 ± 6.27 years, p = 0.29). 
BMI, and waist circumference were slightly 
higher in NASH patients but the differences were not 
significant. Adiponectin level among the obese 
patients with NAFLD was 4.54 ± 2.5454 ng/L while it 
was significantly higher in normal weight healthy 
participants; 6.434 ± 0.796 ng/L (p = 0.004).  
Adiponectin levels and its gene expression in 
liver biopsy in NASH and non-NASH patients are 
shown in Table 3. 
Table 3: Serum Adiponectin level and its liver gene expression 
in NASH and non-NASH patients 
Parameter NASH P value 
Yes 
N = 46 
No 
N = 8 
Adiponectin serum level (ng/L) 4.437 ± 2.569  5.138 ± 2.841 0.519 
Adiponectin receptor liver gene expression 0.8459 ± 0.4671 1.0688 ± 0.3965 0.147 
 
Correlating serum adiponectin level with all 
the clinical and laboratory parameters we assessed 
including liver enzymes, shown no significant 
correlation except for the triglycerides level which was 
negatively correlated with serum adiponectin (r -0.61, 
p < 0.0001). 
 
 
Discussion 
NAFLD represents a spectrum of disorders 
characterized by predominantly macro-vesicular 
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hepatic steatosis that occurs in individuals in the 
absence of consumption of alcohol in amounts 
considered harmful to the liver [16]. NAFLD is a 
leading cause of chronic liver disease and its 
incidence is raising worldwide [17]. 
Measuring serum adiponectin “which is a 
protein hormone secreted by adipocytes” may serve 
as a predictor of progressive liver pathology in 
NAFLD. Adiponectin is an insulin sensitizing hormone 
that has multiple beneficial effects on obesity-related 
medical complications [18]. It was found that serum 
adiponectin level significantly increased after weight 
reduction [19]. 
In the current study, adiponectin serum level 
was significantly lower in NAFLD patients than in 
normal participants (P Value = 0.004); and also its 
level was lower in NASH patients in comparison to 
patients with simple steatosis. 
Several previous studies showed that serum 
adiponectin level was lower in NASH patients than 
non-NASH patients. Also, Baranova and colleagues in 
2006; stated that, serum adiponectin level was the 
only predictor of NASH [20-22]. 
In contrast to this, Savvidou and colleagues in 
2009 founded that serum adiponectin concentration 
was not associated with NAS Score [23]. 
AdipoR1 is abundantly expressed in skeletal 
muscles, whereas adipoR2 is present predominantly 
in the liver [8]. Expression of Adipo R2 significantly 
increased the expression of gene encoding molecules 
involved in glucose uptake such as glucokinase 
(GCK), [27] which appeared to be one possible 
mechanism by which Adipo R2 expression in the liver 
apparently improved diabetes. 
The expression of adiponectin receptors is 
correlated with insulin levels. It has been found that 
their levels are reduced in mouse models of diabetics, 
particularly in skeletal muscle and adipose tissue [26]. 
Also Adipo R1 or Adipo R2 in the liver of mice 
significantly increased fatty-acid oxidation, and tended 
to decrease hepatic triglyceride content [9].  
Recently Adamska et al, 2012 showed that, 
down regulation of Adipo R1 and Adipo R2 in obesity 
plays a causal role at least in the development of 
insulin resistance [5]. 
As a result of this, obesity decreases not only 
plasma adiponectin levels but also Adipo R1/R2 
expression, thereby causing adiponectin resistance 
and leading to insulin resistance, which in turn 
aggravates hyperinsulinaemia forming a 'vicious cycle' 
[10]. 
It has been found that lipid load in adipose 
tissue of obese patients is a source of a pro-
inflammatory systemic environment mechanistically 
implicated in obesity and diet induced insulin 
resistance. This is pro-inflammatory state is 
characterized among others by increased TNF and 
leptin level with a decrease in adiponectin release 
[28]. 
Regarding our study, we found that 
adiponectin receptor gene expression in liver biopsy 
was lower in NASH patients in comparison to non-
NASH patients. 
In parallel with our results, two previous 
studies founded that adiponectin receptor gene 
expression in liver biopsy was lower in NAFLD 
patients, especially in the NASH group [24, 25].  
The result of the current study showed that; 
not only the adiponectin serum level was low in 
patients with NAFLD, but also its level decreased 
more in the presence of NASH rather than simple 
steatosis, and even more the Adipo R gene 
expression in livers of patients with NASH showed a 
lower level than patients with simple steatosis. 
Adipo R2 receptor depletion indicates that, 
not only adiponectin serum level depletion had a role 
in progression of severity of NAFLD, but also 
adiponectin resistance may help in exploring part of 
the missing puzzle in the pathogenesis of NAFLD. 
We should point out some limitations of the 
study, first; the relatively limited number of patients we 
worked on with unequal distribution of sex in the study 
group, second; the unequal distribution of NASH, and 
non-NASH cases, and finally; liver biopsies were 
studied by one pathologist. Our excuse to all these 
limitations that, most of the NAFLD Egyptian patients 
believe that fatty liver is a common benign condition, 
so they refused the idea of liver biopsy. 
In conclusion, both adiponectin deficiency and 
resistance had a role in progression of simple liver 
steatosis to severe injury in obese Egyptian patients. 
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